Aptose Biosciences Inc Stock Price Today (NSE: APS)
Fundamental Score
Aptose Biosciences Inc Share Price Live NSE/BSE & Institutional Fundamental Analysis
Aptose Biosciences Inc share price today is ₹335.00, up +0.00% on NSE/BSE as of 20 February 2026. Aptose Biosciences Inc (APS) is a Small-cap company in the Heavy Electrical Equipment sector with a market capitalisation of ₹856.80 (Cr). The 52-week high for APS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 15.81x, APS is currently trading below its industry average P/E of 47.05x. The company has a Return on Equity (ROE) of 57.82% and a debt-to-equity ratio of 0.23.
Aptose Biosciences Inc Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Aptose Biosciences Inc Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Aptose Biosciences Inc Share Price: A Financial Analysis
In the dynamic Heavy Electrical Equipment sector, characterized by cyclical demand and project-based revenues, maintaining financial efficiency is paramount. This analysis examines Aptose Biosciences Inc share price, currently at ₹378.850006, focusing on key financial metrics and comparing them against sector peers. We aim to provide an objective assessment of the company's financial health and potential for industry dominance. Aptose Biosciences Inc operates within this landscape, facing pressures from fluctuating commodity prices and evolving energy infrastructure needs.
Aptose Biosciences Inc’s PE ratio stands at 15.81, suggesting a market valuation reflective of its earnings. More strikingly, the Return on Capital Employed (ROCE) is an impressive 70.83%. This indicates a high level of efficiency in utilizing capital to generate profits. Such a high ROCE effectively strengthens the company's economic moat, making it more difficult for competitors to erode its market share. This ability to generate significant returns from invested capital is a considerable advantage in a capital-intensive industry.
When comparing Aptose Biosciences Inc with its peers, particularly
Aartech Solonics Ltd, differences in management quality become apparent by the return ratio differences, and also by studying their investor relations approach, which we can observe in publicly available transcripts and presentations. While it is observational, we observe that consistently high ROCE values often correlate with strong leadership and strategic decision-making capabilities.The combination of a reasonable PE ratio and an exceptionally high ROCE suggests that Aptose Biosciences Inc may be undervalued, and possesses strong capital efficiency and is able to generate good revenues from investment which gives it a considerable edge. However, it is essential to consider other factors, such as debt levels, cash flow, and future growth prospects, for a comprehensive evaluation. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra. This is purely observational and not a buy/sell recommendation.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aptose Biosciences Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of APS across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (57.82%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (70.83%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 15.81 vs Industry: 47.05)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (114.41%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (83.88%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (54.16% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (100.09% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (29.70x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (72.52%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Weak Earnings Growth (-49.61% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-5.45 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.56%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Aptose Biosciences Inc Financial Statements
Comprehensive financial data for Aptose Biosciences Inc including income statement, balance sheet and cash flow
About APS (Aptose Biosciences Inc)
Aptose Biosciences Inc (APS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Heavy Electrical Equipment sector with a current market capitalisation of ₹856.80 (Cr). Aptose Biosciences Inc has delivered a Return on Equity (ROE) of 57.82% and a ROCE of 70.83%. The debt-to-equity ratio stands at 0.23, reflecting the company's capital structure. Investors tracking APS share price can monitor key metrics including P/E ratio, promoter holding of 72.52%, and quarterly earnings growth.
Company Details
APS Share Price: Frequently Asked Questions
What is the current share price of Aptose Biosciences Inc (APS)?
As of 20 Feb 2026, 06:09 am IST, Aptose Biosciences Inc share price is ₹335.00. The APS stock has a market capitalisation of ₹856.80 (Cr) on NSE/BSE.
Is APS share price Overvalued or Undervalued?
APS share price is currently trading at a P/E ratio of 15.81x, compared to the industry average of 47.05x. Based on this relative valuation, the Aptose Biosciences Inc stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of APS share price?
The 52-week high of APS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Aptose Biosciences Inc share price?
Key factors influencing APS share price include quarterly earnings growth (Sales Growth: 83.88%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Aptose Biosciences Inc a good stock for long-term investment?
Aptose Biosciences Inc shows a 5-year Profit Growth of 100.09% and an ROE of 57.82%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.23 before investing in APS shares.
How does Aptose Biosciences Inc compare with its industry peers?
Aptose Biosciences Inc competes with major peers in the Heavy Electrical Equipment. Investors should compare APS share price P/E of 15.81x and ROE of 57.82% against the industry averages to determine competitive standing.
What is the P/E ratio of APS and what does it mean?
APS share price has a P/E ratio of 15.81x compared to the industry average of 47.05x. Investors pay ₹16 for every ₹1 of annual earnings.
How is APS performing according to Bull Run's analysis?
APS has a Bull Run fundamental score of 64.6/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does APS belong to?
APS operates in the Heavy Electrical Equipment industry. This classification helps understand the competitive landscape and sector-specific trends affecting Aptose Biosciences Inc share price.
What is Return on Equity (ROE) and why is it important for APS?
APS has an ROE of 57.82%, which indicates excellent management efficiency. ROE measures how efficiently Aptose Biosciences Inc generates profits from shareholders capital.
How is APS debt-to-equity ratio and what does it indicate?
APS has a debt-to-equity ratio of 0.23, which indicates conservative financing with low financial risk.
What is APS dividend yield and is it a good dividend stock?
APS offers a dividend yield of 0.02%, meaning you receive ₹0.02 annual dividend for every ₹100 invested in Aptose Biosciences Inc shares.
How has APS share price grown over the past 5 years?
APS has achieved 5-year growth rates of: Sales Growth 54.16%, Profit Growth 100.09%, and EPS Growth -49.61%.
What is the promoter holding in APS and why does it matter?
Promoters hold 72.52% of APS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Aptose Biosciences Inc.
What is APS market capitalisation category?
APS has a market capitalisation of ₹857 crores, placing it in the Small-cap category.
How volatile is APS stock?
APS has a beta of N/A. A beta > 1 suggests the Aptose Biosciences Inc stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is APS operating profit margin trend?
APS has a 5-year average Operating Profit Margin (OPM) of 9.46%, indicating the company's operational efficiency.
How is APS quarterly performance?
Recent quarterly performance shows Aptose Biosciences Inc YoY Sales Growth of 83.88% and YoY Profit Growth of 114.41%.
What is the institutional holding pattern in APS?
APS has FII holding of 0.00% and DII holding of 0.56%. Significant institutional holding often suggests professional confidence in the Aptose Biosciences Inc stock.